Neuraxpharm and mjn-neuro Collaborate on EPISERAS® Launch
An innovative, non-invasive solution, EPISERAS®, stems from an exciting collaboration between Neuraxpharm and mjn-neuro. This state-of-the-art, AI-powered wearable device continuously monitors brain activity, aiming to detect the risk of seizures in real time. It alerts both patients and caregivers moments before a seizure is anticipated, providing a vital window of opportunity to take precautionary measures.
Transforming Epilepsy Management
The unveiling of EPISERAS® marks a significant leap forward in Neuraxpharm's ongoing commitment to enhancing the safety and quality of life for those living with epilepsy. By merging advanced technology with personalized healthcare, Neuraxpharm is not just supplying medication; this strategic partnership signifies an era of comprehensive care bolstered by digital solutions.
Clinical Study Insights
The product benefits from clinical validation through the SERAS-Home_RWD study. Current interim data from this multicenter research initiative is promising, and forthcoming publications are highly anticipated within the medical community.
An Overview of EPISERAS®’ Technology
Developed by mjn-neuro, this pioneering device resembles a discreet earpiece, designed to seamlessly integrate into the user's daily life. It utilizes sophisticated artificial intelligence to evaluate brain electrical patterns, significantly improving the ability to predict seizures.
Upon identifying heightened seizure risk, EPISERAS® sends timely alerts through a dedicated mobile application. This feature not only benefits patients but also provides caregivers with useful real-time data. Targeting individuals with drug-resistant epilepsy, this innovative approach empowers users by enhancing safety and awareness in daily situations.
Benefits of Early Alert Systems
An early warning can truly be life-changing for epilepsy patients. The ability to respond to alerts allows individuals to relocate to safe environments or seek assistance, thus potentially minimizing the impact of a seizure. EPISERAS® is set to become the first digital solution capable of such proactive management in both homecare and ambulatory healthcare settings.
Statements from Leadership
Dr. Jörg-Thomas Dierks, the CEO of Neuraxpharm, expressed enthusiasm about the launch: "With our digital innovations, we reimagine the landscape of CNS care. Our commitment to patient well-being drives us to integrate cutting-edge technology with therapeutic excellence. This initiative signifies an important milestone aimed at elevating the quality of life for those with epilepsy."
In a parallel statement, David Blánquez, CEO and Co-Founder of mjn-neuro noted, "After over a decade of development and studies, we are thrilled to launch EPISERAS® together with Neuraxpharm. Our collaboration represents a crucial step in bridging technology and patient care, ensuring individuals can lead safer, more fulfilling lives despite their diagnosis."
Strategic Market Entry
As Neuraxpharm gears up for a rollout scheduled for the latter part of 2026, this digital solution will significantly bolster its position within the medical device sector. This strategic move enhances Neuraxpharm's existing product lineup, which includes a diverse portfolio of anti-epileptic treatments. The introduction of EPISERAS® complements traditional therapies, enabling a more personalized and data-driven approach to patient care.
The Origin of a Partnership
Neuraxpharm’s partnership with mjn-neuro commenced in 2022 and illustrates their commitment to advancing technological innovation in neurology. The intersection of medication and wearable technology is rapidly becoming essential in the evolving landscape of healthcare.
Looking Ahead
With a team of approximately 1,000 employees, Neuraxpharm continues to make significant strides in the CNS field, servicing over 20 countries across Europe. The company’s relentless pursuit of innovation through both acquisitions and partnerships positions it well to meet unmet patient needs across various segments.
As research and development efforts proceed, Neuraxpharm anticipates further enhancing its capabilities, ensuring the delivery of effective, personalized healthcare solutions that prioritize patient safety and autonomy.
Frequently Asked Questions
What is EPISERAS®?
EPISERAS® is a digital health solution designed to predict the risk of seizures using an AI-powered wearable device that monitors brain activity.
How does EPISERAS® work?
This wearable device continuously records electrical patterns in the brain, analyzing them to identify when a seizure is likely, providing alerts to users.
Who developed EPISERAS®?
EPISERAS® was developed by mjn-neuro in collaboration with Neuraxpharm, who together aim to enhance the quality of life for individuals living with epilepsy.
When will EPISERAS® be available?
The launch is scheduled for the second half of 2026 across Europe, marking Neuraxpharm's strategic entry into the medical device sector.
What are the benefits of using EPISERAS®?
The device provides early warnings to users, allowing them to take preventive actions, reducing the risk of injuries associated with seizures.
